J Well

J-Well Biotechnology is a clinical-stage biotechnology company based in Taiwan that specializes in the development of advanced cell therapies for oncology and regenerative medicine. The company’s core technology platforms focus on the expansion and activation of Natural Killer (NK) cells and Mesenchymal Stem Cells (MSCs) derived from various tissues. J-Well's pipeline includes autologous NK cell therapies for solid tumors and MSC-based treatments for degenerative conditions such as knee osteoarthritis and liver cirrhosis. The company operates its own Good Tissue Practice (GTP) certified laboratories to ensure the quality and safety of its cell products throughout the clinical trial process. By leveraging the body's innate immune system and regenerative potential, J-Well aims to provide innovative personalized solutions for patients with limited treatment options.